SCHEMBL6894496

SCHEMBL6894496

COC(=O)C1CCN(c2nc3c(-c4cnc5ccccc5c4)cnn3c(N)c2Br)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NEK2 P51955 1/20 0.41
EGFR P00533 3/20 0.39
FGFR2 P21802 3/20 0.39
MAPT P10636 4/20 0.38
KDM4E B2RXH2 2/20 0.38
TP53 P04637 1/20 0.38
PIK3CA P42336 3/20 0.38
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
OGFRL1 Q5TC84 1/20 0.38
AKT1 P31749 2/20 0.37
MTOR P42345 2/20 0.37
LMNA P02545 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TSHR P16473 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KMT2A Q03164 1/20 0.37
HIF1A Q16665 1/20 0.37
RET P07949 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6891513 0.88 FGFR2 (0.37) EGFRFGFR2PIK3CAAKT1MTOR
SCHEMBL6893422 0.87 FGFR2 (0.40) EGFRFGFR2MAPTKDM4ETP53
SCHEMBL594021 0.87 EGFR (0.41) NEK2EGFRFGFR2MAPTKDM4E
SCHEMBL10234073 0.86 FGFR2 (0.41) EGFRFGFR2MAPTKDM4ETP53
SCHEMBL6893425 0.85 PIM1 (0.38) EGFRFGFR2MAPTKDM4ETP53
SCHEMBL6893193 0.84 PDE4B (0.40) EGFRFGFR2PIK3CAOPRM1OPRD1
SCHEMBL2680298 0.84 EGFR (0.40) EGFRFGFR2MAPTKDM4EPIK3CA
SCHEMBL10234123 0.84 CHEK1 (0.37) EGFRFGFR2MAPTKDM4ETP53
SCHEMBL594559 0.82 PIK3CA (0.44) PIK3CAOPRM1OPRD1OGFRL1RET
SCHEMBL6893442 0.82 PIK3CA (0.41) EGFRFGFR2MAPTKDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS BACE1, BACE2, PSEN1 NEK2 2722/4885EGFR 4536/4885FGFR2 3710/4885
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR NEK2 1166/4885EGFR 2799/4885FGFR2 1827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.